murine tissue sections  (R&D Systems)

Journal: EMBO molecular medicine

Article Title: TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.

doi: 10.15252/emmm.201707673

Figure Lengend Snippet: Figure 1. TREM2 expression, glycosylation and proteolysis.

Article Snippet: Murine TREM2 was immunoprecipitated with a rat anti-mTREM2 monoclonal (MAB1729, R&D Systems).

Techniques: Expressing, Glycoproteomics

Journal: EMBO molecular medicine

Article Title: TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.

doi: 10.15252/emmm.201707673

Figure Lengend Snippet: Figure 2. Shedding of glycosylated TREM2 NTF is sensitive to inhibitors of ADAM10 and matrix metalloproteinases.

Article Snippet: Murine TREM2 was immunoprecipitated with a rat anti-mTREM2 monoclonal (MAB1729, R&D Systems).

Techniques:

Journal: EMBO molecular medicine

Article Title: TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.

doi: 10.15252/emmm.201707673

Figure Lengend Snippet: Figure 6. Knock-down of ADAM10 is less effective at reducing the shedding of H157Y TREM2.

Article Snippet: Murine TREM2 was immunoprecipitated with a rat anti-mTREM2 monoclonal (MAB1729, R&D Systems).

Techniques: Knockdown

Journal: EMBO Molecular Medicine

Article Title: TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

doi: 10.15252/emmm.201606370

Figure Lengend Snippet: Schematic of the mouse Trem2 locus and the TREM2 protein. Sequence alignment of wild‐type N9 (N9 wt) and TREM2 mutant N9 (N9 mu) surrounding the gRNA target site. The gRNA sequence is in cyan, and protospacer‐adjacent motif (PAM) is marked with a line. The single nucleotide insertion is labeled in red. Schematic representation of wild‐type TREM2 (NP_112544.1) and CRISPR/Cas9‐modified TREM2 (N9 mu). TM, transmembrane domain; SP, signal peptide. Western blot analysis of lysates and media from wt and mutant N9 cells (N9 wt /mu) using the antibody anti‐murine TREM2 (clone 5F4), which is raised against the murine TREM2 extracellular domain. sTREM2, soluble TREM2. *indicate unspecific bands. Calnexin was used as a loading control. Phagocytosis of 1 μM HiLyte ™ Fluor 488 Aβ 1‐42 (fAβ 42 ) by N9 wt and N9 mu in the presence or absence of antibody 2D8 or the non‐binding antibody 6687. Cytochalasin D (CytoD, 10 mM) was used as control to verify phagocytic uptake. ( n = 4, ± SEM; two‐way ANOVA, interaction P = 0.61, genotype P < 0.0001, treatment P = 0.0001; post hoc tests wt vs. mu for the following conditions: fAβ 42 P = 0.0043, fAβ 42 ‐2D8 P = 0.0436). Western blot of BMDM derived from wt and Trem2 knockout (ko) animals using antibody 5F4. *indicate unspecific bands. Phagocytosis of fAβ 42 by BMDM from wt and Trem2 ko animals in the presence or absence of 2D8, or the non‐binding control antibody 6687. ( n = 3, ± SEM; two‐way ANOVA, interaction P = 0.0005, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ 42 P = 0.0021, fAβ 42 ‐2D8 1 μg/ml P < 0.0001, fAβ 42 ‐2D8 5 μg/ml P < 0.0001, fAβ 42 ‐2D8 10 μg/ml P < 0.0001, fAβ 42 /6687 10 μg/ml P = 0.0007). Quantification of relative fAβ 42 uptake to lowest antibody concentration used ( n = 3, ± SEM). Phagocytosis of fAβ 42 by BMDM from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). ( n = 4, ± SEM; two‐way ANOVA, interaction P = 0.0223, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ 42 ‐mAb11 1 μg/ml P = 0.0391, fAβ 42 ‐mAb11 5 μg/ml P = 0.0069, fAβ 42 ‐mAb11 10 μg/ml P < 0.0001, fAβ 42 ‐mAb11 20 μg/ml P = 0.0001, fAβ 42 ‐mAb11 50 μg/ml P < 0.0001). Quantification of relative fAβ 42 uptake to lowest antibody concentration used ( n = 4, ± SEM). Recombinant mouse sTREM2 does not rescue fAβ 42 uptake in Trem2 ‐deficient BMDM. Increasing amounts of sTREM2 were added to the media of wt or Trem2 ko BMDM in the presence or absence of mAb11 (10 μg/ml) ( n = 4, ± SEM). Western blot of primary microglia from wt or Trem2 ko animals using antibody 5F4. *indicate unspecific bands. Phagocytosis of fAβ 42 by primary microglia from wt and Trem2 ko animals in the presence or absence of mAb11, or an isotype control antibody (IC). ( n = 5, ± SEM; two‐way ANOVA, interaction P = 0.4797, genotype P < 0.0001, treatment P < 0.0001; post hoc tests wt vs. ko for the following conditions: fAβ 42 ‐mAb11 5 μg/ml P = 0.0449, fAβ 42 ‐mAb11 10 μg/ml P = 0.0370, fAβ 42 ‐mAb11 20 μg/ml P = 0.0299, fAβ 42 ‐mAb11 50 μg/ml P = 0.0120). Quantification of relative fAβ 42 uptake to lowest antibody concentration used ( n = 5, ± SEM). Data information: (C, E, G, K) Quantification of internalized fAβ 42 was normalized to wt without antibody. Bonferroni‐corrected pair‐wise post hoc tests were used. Source data are available online for this figure.

Article Snippet: For Western blotting of TREM2, we raised a rat monoclonal antibody (clone 5F4; 1:50) against the extracellular domain of murine TREM2 (Creative Biomart; Trem2‐3276M).

Techniques: Sequencing, Mutagenesis, Labeling, CRISPR, Modification, Western Blot, Control, Binding Assay, Derivative Assay, Knock-Out, Concentration Assay, Recombinant

Journal: EMBO Molecular Medicine

Article Title: TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

doi: 10.15252/emmm.201606370

Figure Lengend Snippet: Representative histograms for Fcγ‐receptors‐PE (FcγR‐PE) expression levels as used for quantification. Stacked histograms for log PE fluorescence intensity of wt and Trem2 ko BMDM are shown for the respective FcγR (I, IIB/III, and IV). Relative quantification of cell surface levels of FcγR molecules. Absolute number of cell surface FcγR‐PE molecules was determined by the BD QuantiBRITE® method (see methods section for details) and normalized to expression levels of the respective wt control. ( n = 4, ± SEM, t ‐test, two‐tailed; wt vs. ko: FcγRI‐PE P = 0.0008, FcγRIIB/III‐PE P = 0.0033, FcγRIV‐PE P = 0.7001). mRNA levels of FcγR are increased in Trem2 ko BMDM. Fold changes of the respective FcγR (I, IIB, III, IV) mRNA levels in Trem2 ko BMDM were determined by quantitative real‐time PCR. ( n = 6, ± SEM; one‐sample t ‐test, two‐tailed; wt vs. ko: FcγRI P = 0.0118, FcγRIIB P = 0.0006, FcγRIII P = 0.0004, FcγRIV P = 0.0284) Phosphorylated Syk (P‐Syk) and total Syk (T‐Syk) levels were determined by Western blotting in lysates from wt and Trem2 ko BMDM after 1 h treatment with Aβ alone, together with antibody 2D8 (Aβ‐2D8), or an isotype control (Aβ‐IC). Actin was used as a loading control. Quantification of P‐Syk normalized to T‐Syk. ( n = 4, ± SEM; 2 way ANOVA, interaction P = 0.0490, genotype P = 0.0898, treatment P < 0.0001. Bonferroni‐corrected pair‐wise post hoc tests, ** P = 0.0075 vs. wt). Source data are available online for this figure.

Article Snippet: For Western blotting of TREM2, we raised a rat monoclonal antibody (clone 5F4; 1:50) against the extracellular domain of murine TREM2 (Creative Biomart; Trem2‐3276M).

Techniques: Expressing, Fluorescence, Quantitative Proteomics, Control, Two Tailed Test, Real-time Polymerase Chain Reaction, Western Blot

Journal: EMBO Molecular Medicine

Article Title: TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

doi: 10.15252/emmm.201606370

Figure Lengend Snippet: A BMDM from wt or Trem2 ko mice were cultured on APP/PS1 mice brain cryosections incubated with or without mAb11 (1 μg/ml) or an isotype control (IC; 1 μg/ml) for 24 h. Sections were then probed with methoxy‐X04. Scale bar, 500 μm. B The amyloid plaque load was quantified from the entire sagittal section. Sections incubated with medium (no cell) were set as baseline. ( n = 6, ± SEM; two‐way ANOVA, interaction P < 0.0001, genotype P < 0.0001, treatment P < 0.0001; Tukey's multiple comparisons tests; wt vs. ko for the following conditions: no antibody P = 0.0304, IC P = 0.0049, mAb11 P = 0.0212; wt: IC vs. wt: mAb11 P = 0.0008; ko: IC vs. ko: mAb11 P = 0.0001). C, D Equal numbers of wt and Trem2 ko BMDM were added, and cell numbers were analyzed after termination of experiments by quantifying the CD68‐positive cells on top of the sections. ( n = 4, ± SEM; t ‐test; n.s., non‐significant, P = 0.5004). Scale bar, 200 μm. E Aβ was extracted by urea buffer from replicate slices of the experiment shown in (A), and total Aβ was identified by Western blotting. Source data are available online for this figure.

Article Snippet: For Western blotting of TREM2, we raised a rat monoclonal antibody (clone 5F4; 1:50) against the extracellular domain of murine TREM2 (Creative Biomart; Trem2‐3276M).

Techniques: Cell Culture, Incubation, Control, Western Blot

Journal: EMBO Molecular Medicine

Article Title: TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance

doi: 10.15252/emmm.201606370

Figure Lengend Snippet: Cryosections from unfixed brain of 6‐month‐old APP/PS1 mice were pre‐incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 μg/ml). BMDM from wt or Trem2 ko mice were added for 24 h. Sections were stained with methoxy‐X04. Scale bar, 500 μm. Methoxy‐X04 signals were quantified from the entire sagittal section. ( n = 5, ± SEM; two‐way ANOVA, interaction P = 0.0082, genotype P < 0.0001, treatment P < 0.0001. Fisher's LSD post hoc comparisons; * show statistics between wt and ko under the same experimental condition. # in black shows wt compares to no‐antibody stimulation; # in gray shows ko compares to no‐antibody stimulation; wt vs. ko for the following conditions: no antibody P = 0.0053, mAb11 0.001 μg/ml P = 0.0003, mAb11 0.01 μg/ml P < 0.0001, mAb11 0.1 μg/ml P = 0.0001, mAb11 1 μg/ml P = 0.0007, mAb11 5 μg/ml P = 0.0011; following conditions compare to wt/no antibody: wt/mAb11 0.01 μg/ml P = 0.0166, wt/mAb11 0.1 μg/ml P = 0.0002, wt/mAb11 1 μg/ml P < 0.0001, wt/mAb11 5 μg/ml P < 0.0001; following conditions compare to ko/no antibody: ko/mAb11 0.1 μg/ml P = 0.0099, ko/mAb11 1 μg/ml P < 0.0001, ko/mAb11 5 μg/ml P < 0.0001.

Article Snippet: For Western blotting of TREM2, we raised a rat monoclonal antibody (clone 5F4; 1:50) against the extracellular domain of murine TREM2 (Creative Biomart; Trem2‐3276M).

Techniques: Incubation, Staining